Extended Weight Loss Programmes Deliver Lasting Benefits
Weight management remains a pressing issue across the UK, with obesity driving up rates of diabetes, heart disease, and hypertension. The NHS has long relied on 12-week commercial weight loss programmes, such as those run by Weight Watchers, to help individuals shed excess weight. But how effective are these short interventions over the long term? A study published in The Lancet on 4 May 2017 provides a clear answer: extending support to a full year not only helps people maintain weight loss but also improves health outcomes and proves highly cost-effective for the NHS.
The WRAP Trial: A Landmark Study
The Weight Loss Referrals for Adults in Primary Care (WRAP) trial, led by researchers from the Universities of Cambridge, Liverpool, and Oxford, compared different weight loss strategies for adults with a BMI of 28 or higher. The study involved 1,267 participants randomly assigned to:
- A self-help group with an advice booklet
- A standard 12-week commercial weight loss programme
- An extended 52-week (year-long) programme
Weight Loss Results: Longer Programmes Work Better
After one year:
- Self-help: 3.3kg lost
- 12-week programme: 4.8kg lost
- Year-long programme: 6.8kg lost
Even after two years, the year-long group remained 4.3kg lighter, compared to 3.0kg in the 12-week group and 2.3kg in self-help participants. Longer programmes support better weight loss maintenance and more sustainable results.
Health Benefits Beyond the Scales
Extending programmes also provides critical health benefits. Participants in the year-long group showed significant improvements in diabetes markers, such as fasting blood glucose and HbA1c.
- Blood glucose reduction after one year:
- Self-help: 0.11 mmol/L
- 12-week: 0.27 mmol/L
- Year-long: 0.54 mmol/L
These improvements reduce the risk of developing type 2 diabetes and other metabolic conditions, highlighting the broader health benefits of sustained support.
Cost-Effectiveness: A Smart Investment
Economic analysis over 25 years demonstrated that while the 12-week programme saved the NHS £268,000 per 100,000 people, the year-long programme prevented an additional 1,786 cases of chronic disease, including 373 diabetes cases, and remained highly cost-effective. The cost per QALY (quality-adjusted life year) gained was well below the NICE threshold of £20,000, showing that longer programmes are a worthwhile investment.
Expert Commentary
Professor Susan Jebb (University of Oxford) stated:
“Offering longer-term support through weight loss groups helps people keep weight off and is cost-effective by preventing diseases like diabetes and heart disease.”
Lead author Dr Amy Ahern (MRC Epidemiology Unit, University of Cambridge) added:
“Extending a commercial programme to a full year leads to sustained weight loss and greater health benefits, comparable to much more expensive interventions.”
Dr Emily Brindal (CSIRO) noted:
“Prolonged access to weight loss programmes is a simple, scalable way to improve long-term outcomes.”
Policy Implications
The WRAP trial strongly supports extending access to year-long programmes. While ensuring access to the standard 12-week programme remains a priority, providing longer-term support can deliver even greater health and economic benefits, particularly in reducing obesity-related diseases like diabetes.
Conclusion
Extended weight loss programmes help participants lose more weight, maintain it, and achieve better health outcomes. While longer programmes require greater upfront investment, they are highly cost-effective and play a crucial role in preventing obesity-related chronic diseases such as diabetes. For the NHS and individuals alike, the evidence makes a persuasive case: longer really is better.
